Future studies should particularly focus on the practical clinical value of HMGB1 and IL-6, including developing a scoring system with plasma HMGB1 and IL-6 as biomarkers for early recognition of COVID-19 patients at risk for developing severe disease. This evidence concerns the gene HMGB1 and COVID-19.